BRPI0518247A2 - composiÇÕes compreendo inibidores de cinases jun n-terminais e uso - Google Patents

composiÇÕes compreendo inibidores de cinases jun n-terminais e uso

Info

Publication number
BRPI0518247A2
BRPI0518247A2 BRPI0518247-6A BRPI0518247A BRPI0518247A2 BR PI0518247 A2 BRPI0518247 A2 BR PI0518247A2 BR PI0518247 A BRPI0518247 A BR PI0518247A BR PI0518247 A2 BRPI0518247 A2 BR PI0518247A2
Authority
BR
Brazil
Prior art keywords
compositions
jun
kinase inhibitors
terminal kinase
terminal
Prior art date
Application number
BRPI0518247-6A
Other languages
English (en)
Inventor
Iok-Hou Pang
Abbot F Clark
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BRPI0518247A2 publication Critical patent/BRPI0518247A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSIÇÕES COMPREENDENDO INIBIDORES DE CINASES JUN N-TERMINAIS E USO. A presente invenção refere-se às composições e métodos para o tratamento de glaucoma e outras doenças oculares. As composições e métodos são particularmente direcionados ao uso de inibidores das cinases Jun N - terminais (JNK), tais como SP600125 no tratamento de glaucoma e outras doenças oculares.
BRPI0518247-6A 2004-10-29 2005-10-27 composiÇÕes compreendo inibidores de cinases jun n-terminais e uso BRPI0518247A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62375504P 2004-10-29 2004-10-29
PCT/US2005/038825 WO2006050045A2 (en) 2004-10-29 2005-10-27 Inhibitors of jun n-terminal kinases for treating glaucomatous retinopathy and ocular diseases

Publications (1)

Publication Number Publication Date
BRPI0518247A2 true BRPI0518247A2 (pt) 2008-11-11

Family

ID=35828365

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518247-6A BRPI0518247A2 (pt) 2004-10-29 2005-10-27 composiÇÕes compreendo inibidores de cinases jun n-terminais e uso

Country Status (13)

Country Link
US (2) US20060094753A1 (pt)
EP (2) EP2248521A1 (pt)
JP (1) JP2008518922A (pt)
KR (1) KR101234518B1 (pt)
CN (2) CN102166358A (pt)
AR (1) AR051472A1 (pt)
AU (1) AU2005302511B2 (pt)
BR (1) BRPI0518247A2 (pt)
CA (1) CA2582316C (pt)
MX (1) MX2007004264A (pt)
TW (1) TWI377940B (pt)
WO (1) WO2006050045A2 (pt)
ZA (1) ZA200703990B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US20080051319A1 (en) * 2006-08-22 2008-02-28 Children's Medical Center Corporation Inhibiting JNK Signaling Promotes CNS Axon Regeneration
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
JP2010254672A (ja) 2009-03-30 2010-11-11 Santen Pharmaceut Co Ltd ＪＮＫ（ｃ−Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを有効成分として含有する網膜疾患の予防または治療剤
US20120077753A1 (en) * 2009-06-25 2012-03-29 Laxman Gangwani Jnk inhibitors for use in treating spinal muscular atrophy
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US20130288981A1 (en) * 2012-04-02 2013-10-31 Buck Institute For Research On Aging Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CN105307670A (zh) * 2013-06-26 2016-02-03 埃克西金炎症有限公司 Jnk信号转导途径的细胞渗透肽抑制剂用于治疗多种疾病的新用途
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CN113509541A (zh) * 2014-06-26 2021-10-19 埃克西金炎症有限公司 Jnk信号转导途径的细胞穿透肽抑制剂用于治疗多种疾病的新用途
CN109303782A (zh) * 2018-10-24 2019-02-05 厦门大学 Jnk-in-8在制备干性年龄相关性黄斑变性的神经保护剂中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
CN1323208A (zh) * 1998-10-13 2001-11-21 协和发酵工业株式会社 眼病治疗剂
CA2354402A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles as protein kinase inhibitors
DK1149092T3 (da) 1998-12-17 2004-02-23 Hoffmann La Roche 4- og 5-alkynyloxindoler og 4- og 5-alkenyloxindoler
BR9916223A (pt) 1998-12-17 2001-09-04 Hoffmann La Roche 4-ariloxindóis como inibidores de cinases de proteìna jnk
ATE425142T1 (de) * 1999-04-23 2009-03-15 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
JP2003531103A (ja) 1999-08-12 2003-10-21 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−ＪＵＮＮ−末端キナーゼ（ＪＮＫ）および他のタンパク質キナーゼの阻害剤
US20040072888A1 (en) * 1999-08-19 2004-04-15 Bennett Brydon L. Methods for treating inflammatory conditions or inhibiting JNK
WO2001012609A1 (en) * 1999-08-19 2001-02-22 Signal Pharmaceuticals, Inc. Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1110957A1 (en) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
WO2001058448A1 (fr) * 2000-02-09 2001-08-16 Shionogi & Co., Ltd. Inhibiteur d'apoptose
WO2001064872A2 (en) * 2000-02-29 2001-09-07 Millennium Pharmaceuticals, Inc. Gene 2465: methods and compositions for the diagnosis and treatment of cardiovascular, hepatic and bone disease
WO2001091749A1 (en) 2000-06-01 2001-12-06 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
EP1193256A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
JP2002302445A (ja) * 2001-02-02 2002-10-18 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
WO2002062792A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
EP1357912B9 (en) * 2001-02-06 2012-06-13 QLT Inc. Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
AU2002255263B2 (en) 2001-04-16 2006-12-14 Eisai R&D Management Co., Ltd. Novel 1H-indazole compound
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
CA2458131A1 (en) * 2001-08-23 2003-03-06 Takeda Chemical Industries, Ltd. Jnk activation inhibitor
MXPA04002243A (es) 2001-09-19 2004-06-29 Aventis Pharma Sa Compuestos quimicos.
US7390797B2 (en) * 2002-02-28 2008-06-24 Eisai Co., Ltd. Fused indazole compounds
CA2488013A1 (en) * 2002-05-30 2003-12-11 Celgene Corporation Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes
WO2003106455A1 (en) * 2002-06-14 2003-12-24 Applied Research Systems Ars Holding N.V. Azole methylidene cyanide derivatives and their use as protein kinase modulators
JP2006502183A (ja) * 2002-09-20 2006-01-19 アルコン，インコーポレイテッド ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用
US20040092568A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods for the treatment, prevention and management of macular degeneration
WO2004106543A1 (en) * 2003-05-30 2004-12-09 Phylogica Limited An improved genetic screen for interaction interface mapping
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma

Also Published As

Publication number Publication date
US20100280089A1 (en) 2010-11-04
ZA200703990B (en) 2008-09-25
AU2005302511B2 (en) 2011-07-14
TWI377940B (en) 2012-12-01
CN101048156A (zh) 2007-10-03
WO2006050045A2 (en) 2006-05-11
JP2008518922A (ja) 2008-06-05
TW200621236A (en) 2006-07-01
CA2582316C (en) 2012-04-03
US20060094753A1 (en) 2006-05-04
AU2005302511A1 (en) 2006-05-11
AR051472A1 (es) 2007-01-17
KR101234518B1 (ko) 2013-02-19
MX2007004264A (es) 2007-06-15
CN101048156B (zh) 2011-06-15
EP1804790A2 (en) 2007-07-11
KR20070070208A (ko) 2007-07-03
CA2582316A1 (en) 2006-05-11
CN102166358A (zh) 2011-08-31
WO2006050045A3 (en) 2006-12-07
EP2248521A1 (en) 2010-11-10

Similar Documents

Publication Publication Date Title
BRPI0518247A2 (pt) composiÇÕes compreendo inibidores de cinases jun n-terminais e uso
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
NO20073068L (no) Stereoisomere anrikete 3-aminokarbonylbisykloheptenpyrimidindiaminforindelser og deres anvendelse
NI201100063A (es) Inhibidores de las enzimas de proteína cinasa activadas por mitógeno p38.
UA95105C2 (ru) Применение производного лактамида для снижения токсичности в препарате, который может соприкасаться с кожей или глазами человека или животного, производные лактамида и способы их получения
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
CL2004002050A1 (es) Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
CL2007002492A1 (es) Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras.
ECSP077985A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
EA201101666A1 (ru) 3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ]ОКТАН- ИЛИ ГЕПТАННИТРИЛ КАК JAK-ИНГИБИТОРЫ
NO20084435L (no) C-MET proteinkinaseinhibitorer
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20072747L (no) Fremgangsmate for fremstilling av indazolforbindelser
CR20110230A (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
UA85559C2 (en) Aminobenzophenone compounds
CL2011000489A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala
MX2009004623A (es) Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
NO20070502L (no) Azaindoler nyttige som inhibitorer av proteinkinaser

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.